Clark Capital Management Group Inc. Has $824,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Clark Capital Management Group Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,054 shares of the biopharmaceutical company’s stock after selling 1,186 shares during the quarter. Clark Capital Management Group Inc.’s holdings in Pfizer were worth $824,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer during the fourth quarter worth $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at $28,000. Finally, Noble Wealth Management PBC bought a new position in shares of Pfizer in the 4th quarter valued at $31,000. Institutional investors own 68.36% of the company’s stock.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Trading Down 3.0 %

NYSE:PFE opened at $22.28 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm’s fifty day moving average is $24.02 and its 200-day moving average is $25.56. The firm has a market cap of $126.36 billion, a P/E ratio of 15.80, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company posted $0.82 EPS. The business’s quarterly revenue was down 7.8% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.72%. The ex-dividend date is Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.